Study of genetic mutation in metastatic oral cancers
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: C770- Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck
- Registration Number
- CTRI/2024/06/069428
- Lead Sponsor
- Maulana Azad Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Newly diagnosed cases of nodal metastasis in oral squamous cell carcinoma.
Exclusion Criteria
Cases with inadequate material, or with extensive hemorrhage.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) Prevalence of expression of EGFR and VEGF in metastatic oral squamous cell carcinoma <br/ ><br>2) Expression of EGFR mutations in metastatic oral squamous cell carcinomaTimepoint: Baseline
- Secondary Outcome Measures
Name Time Method Correlation between expression of EGFR and VEGF and EFGR mutations with response to therapyTimepoint: Baseline
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the relationship between EGFR mutation status and VEGF expression in metastatic oral squamous cell carcinoma (CTRI/2024/06/069428)?
How do EGFR and VEGF biomarkers influence patient selection for targeted therapies in head and neck lymph node metastases?
What molecular mechanisms link EGFR mutations to metastatic progression in oral squamous cell carcinoma (C770)?
Are there comparative studies on EGFR-targeted therapies versus standard-of-care for metastatic oral cancers with specific mutations?
What adverse events are associated with anti-VEGF and EGFR inhibition in metastatic oral squamous cell carcinoma patients?